UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) ~~July~~January 2019, ~~2010~~2011

APPLIED NEUROSOLUTIONS, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware 001-13835 39-1661164

Delaware		001-13835		39-1661164
(State or Other Jurisdiction of Incorporation)		(Commission file Number)		(IRS Employer Identification No.)

(State or Other Jurisdiction (Commission file Number) (IRS Employer

50 Lakeview Parkway, Suite 111, Vernon Hills, IL		60061
(Address of Principal Executive Offices)		(Zip Code)

of Incorporation) Identification No.)

50 Lakeview Parkway, Suite 111, Vernon Hills, IL 60061

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code (847) 573-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 18 – ~~Registrant’s~~Other ~~Business and Operations~~Events

Item 18.~~02.~~01 ~~Termination~~– ofOther ~~a Material Definitive Agreement.~~Events

~~On May 12, 2010,~~ Applied NeuroSolutions, Inc. (the “Registrant”) ~~received~~has ~~correspondence~~previously ~~from~~disclosed ~~counsel~~its ~~for~~need ~~Albert~~to ~~Einstein~~raise ~~College~~funds ofto ~~Medicine~~continue ofits ~~Yeshiva~~operations ~~University~~as ~~(“AECOM”)~~a ~~notifying~~virtual ~~the~~company. The Registrant ~~that~~had ~~AECOM~~discontinued ~~claimed~~funding ~~the Registrant was in breach of~~ its ~~exclusive~~Alzheimer’s ~~licensing~~disease ~~agreements~~ (~~the~~ “~~Agreements~~AD”) ~~with~~diagnostic ~~AECOM. The~~programs, ~~Agreements~~terminated ~~provide~~all aemployees ~~sixty-day~~and ~~cure~~shut ~~period~~down ~~for~~its ~~any~~office ~~breach~~and lab space. ~~AECOM~~Due ~~agreed~~ to ~~extend~~ the ~~cure~~lack ~~period~~of ~~until July 20~~funding, ~~2010~~the asRegistrant ~~negotiations~~lost ~~continued. The~~the ~~Registrant~~exclusive ~~was~~licensing ~~not~~rights ~~able~~ to ~~cure~~its ~~the~~AD ~~breach~~technology ~~prior~~with toAlbert ~~the~~Einstein ~~end~~College of ~~the~~Medicine ~~extended~~of ~~cure~~Yeshiva ~~period and the Agreements were terminated~~University.

The ~~Agreements provided the~~ Registrant ~~with~~has ~~exclusive~~not ~~licenses~~been ~~from~~able ~~AECOM~~to ~~covering~~secure ~~virtually~~funding, ~~all~~thus, of the Registrant’s ~~Alzheimer's~~Board ~~disease~~of ~~(“AD”)~~Directors ~~technology,~~has ~~including~~elected ~~virtually~~to ~~all~~cease ~~its~~the ~~AD related diagnostic and therapeutic products currently in development. The~~ Registrant’s ~~depended~~operations, oneffective ~~these licensing arrangements to maintain full rights to its products under development~~immediately.

~~The~~Section 5 ~~Registrant~~– isCorporate ~~currently~~Governance ~~in default of its collaboration agreement with Eli Lilly~~ and Company (“Lilly”) due to the termination of the Agreements with AECOM. Lilly has the right to terminate the Lilly agreement upon an event of default, if the event of default is not cured by the Registrant within 90 days from Lilly’s notification to the Registrant. If Lilly terminates the collaboration agreement due to the default, Lilly would be obligated to pay the Registrant 50% of all fees, milestone payments and royalties, which are specified in the collaboration agreement.Management

~~The~~Item ~~Registrant~~5.02. is– inDeparture ~~discussions~~of toDirectors ~~obtain~~or ~~funding~~Certain ~~for~~Officers; aElection ~~virtual~~of ~~company~~Directors; ~~that~~Appointment ~~would~~of ~~maintain~~Certain ~~its~~Officers; ~~operations~~Compensatory ~~solely~~Arrangements toof ~~support~~Certain ~~its drug development collaboration with Lilly~~Officers.

On January 19, 2011, in conjunction with the items outlined above, the Board of Directors of the Registrant, Ellen R. Hoffing, Edward A. Ogunro, Ph.D., Gary C. Parks and David C. Tiemeier, Ph.D., resigned. In addition, David Ellison, the acting CEO and CFO also resigned.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this ~~23rd~~19th day of ~~July~~January ~~2010~~2011.

APPLIED NEUROSOLUTIONS, INC. By: /s/ David Ellison Name: David Ellison Title: Acting CEO and CFO

~~By: /s/David Ellison~~ 2

Name: David Ellison

Title: Acting CEO and CFO

Filing Compare · APPLIED NEUROSOLUTIONS INC